Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gensight BiologicsGSGTF EV-to-OCF is -3.10 as of Aug. 14, 2026. The stock has 8 warning signs investors should review. Among 1,410 Biotechnology companies, Gensight Biologics ranks worse than 51.56% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Gensight Biologics's Enterprise Value is $33.15 Mil.
Gensight Biologics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-10.69 Mil. Therefore, Gensight Biologics's EV-to-OCF for today is -3.10.
The historical rank and industry rank for Gensight Biologics's EV-to-OCF or its related term are showing as below:
GSGTF'
s EV-to-OCF Range Over the Past 10 Years
Min: -19.45 Med: -2.56 Max: -0.62
Current: -3.37
During the past 13 years, the highest EV-to-OCF of Gensight Biologics was -0.62. The lowest was -19.45. And the median was -2.56.
GSGTF's EV-to-OCF is ranked worse than 51.56% of 1410
companies
in the Biotechnology industry
Industry Median: -3.52
vs GSGTF: -3.37
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Gensight Biologics's PE Ratio (TTM) for today is calculated as:
Gensight Biologics's share price for today is $0.09.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.093.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Gensight Biologics EV-to-OCF Related Terms
Gensight Biologics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Gensight Biologics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gensight Biologics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's EV-to-OCF falls into.
Gensight Biologics's current Enterprise Value is $33.15 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Gensight Biologics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-10.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gensight Biologics (GSGTF) has a EV-to-OCF of -3.10 as of Aug. 14, 2026. According to the industry distribution chart, Gensight Biologics ranks #727 out of 1410 companies in the Biotechnology industry, placing it in the top 51.6%.
Is Gensight Biologics' EV-to-OCF too high?
Gensight Biologics' current EV-to-OCF is -3.10. Based on the distribution chart, Gensight Biologics ranks #727 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint.
How does Gensight Biologics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #727 out of 1410 companies for EV-to-OCF. This places Gensight Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Gensight Biologics's current EV-to-OCF is -3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Gensight Biologics (GSGTF) has a current EV-to-OCF of -3.10. The current EV-to-OCF is -3.10. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current EV-to-OCF is -3.10 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GSGTF has been successfully added to your 
